Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 7/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923005 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL744198 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17760540 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL4531927 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3673559 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL746205 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL25286686 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL418951 | 0.82 | ATM (0.59) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL16751022 | 0.82 | ATM (0.59) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17511112 | 0.80 | ATM (0.42) | ATMPIK3CDDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006060548-A2 | NOVEL DERMATOLOGICAL COMPOSITION USING BIO-ACTIVATING ORGANOCATALYSTS | EBERSYTES, LLC (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060120980-A1 | Novel dermatological composition using bio-activating organocatalysts | EBERSYTES, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2006060548-A2 | NOVEL DERMATOLOGICAL COMPOSITION USING BIO-ACTIVATING ORGANOCATALYSTS | EBERSYTES, LLC (US) | 2006-06-08 | — | — | WO | disclosed |
| US-6329418-B1 | ESPECIALLY USEFUL FOR INHIBITING ZINC METALLOPROTEASES | THE PROCTER & GAMBLE COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1073635-A1 | SUBSTITUTED PYRROLIDINE HYDROXAMATE METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999052868-A1 | SUBSTITUTED PYRROLIDINE HYDROXAMATE METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060120980-A1 | Novel dermatological composition using bio-activating organocatalysts | FGF1, FGF2, FGFR3 | ATM 4196/4885PIK3CD 411/4885DPP4 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.